Stifel Initiates Coverage On C4 Therapeutics with Hold Rating, Announces Price Target of $45
Stifel analyst Bradley Canino initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Hold rating and announces Price Target of $45.
C4 Therapeutics Insider Trades $1.06 Million In Company Stock
Elena Prokupets, Director at C4 Therapeutics (NASDAQ:CCCC), made a large insider sell on September 21, according to a new SEC filing.
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen’s Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 13)
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 9)
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)
C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag
The FDA has granted Orphan Drug Designation to C4 Therapeutics Inc (NASDAQ:CCCC) CFT7455 for multiple myeloma. CFT7455 is an orally bioavailable MonoDAC…
Brookline Capital Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $54
Brookline Capital initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $54.
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 14)